Sandoz Plans Generic Semaglutide Launch in Canada with Up to 70% Price Reduction

Swiss generic drug manufacturer Sandoz查看公司主页 plans to launch unbranded weight-loss drugs in Canada at discounts of up to 70% compared to branded versions once patents begin to expire next year, CEO Richard Saynor told the Financial Times. The announcement signals a potential major shift in accessibility for GLP-1 receptor (搜索)搜索该靶点 agonist medications that have transformed obesity (搜索)搜索该疾病 and diabetes (搜索)搜索该疾病 treatment.

Significant Price Reductions Expected

Sandoz查看公司主页 is yet to finalize the pricing for its generic weight-loss and diabetes (搜索)搜索该疾病 drug semaglutide查看药品详情, but a price cut of "60 or 70 per cent of the list price" was achievable, Saynor told the newspaper. The CEO suggested prices could drop even further as more generic versions become available in the market.

"If you were selling this at $40 or $50 a month, the market could be two or three times bigger in terms of the number of patients," Saynor noted, highlighting the potential for dramatically expanded patient access.

Currently, branded weight-loss and diabetes (搜索)搜索该疾病 medications, such as Novo Nordisk查看公司主页's Ozempic查看药品详情 and Wegovy查看药品详情, and Eli Lilly查看公司主页's Mounjaro查看药品详情 and Zepbound查看药品详情, are priced between $200 and $400 for a one-month supply, according to the Financial Times report.

Market Context and Competition

The move comes as demand for weight-loss and diabetes (搜索)搜索该疾病 drugs has surged globally, driven by their effectiveness in managing obesity (搜索)搜索该疾病 and diabetes. Novo Nordisk查看公司主页's medications use semaglutide查看药品详情 as the active ingredient, while Eli Lilly查看公司主页's medications use tirzepatide查看药品详情.

Sandoz查看公司主页 is not alone in preparing for the generic market entry. Last month, a top Biocon查看公司主页 executive told Reuters that the biopharmaceutical company aims to launch generic copies of the blockbuster weight-loss drug Wegovy查看药品详情 in Canada within the next two years.

Company Clarification

A spokesperson for Sandoz查看公司主页 confirmed Saynor's remarks to the Financial Times, but clarified that he was speaking in general terms about typical price reductions for generics once patents expire, and was not indicating specific pricing plans for Sandoz's semaglutide查看药品详情. This suggests the company is still developing its precise market strategy while patents remain in effect.

The anticipated entry of generic versions represents a significant development for patients who have faced high costs and limited access to these highly effective medications for weight management and diabetes (搜索)搜索该疾病 control.